Neoadjuvant Treatment Options in Soft Tissue Sarcomas.
Mateusz Jacek SpałekKatarzyna KozakAnna Małgorzata CzarneckaEwa BartnikAneta BorkowskaPiotr Lukasz RutkowskiPublished in: Cancers (2020)
Due to the heterogeneity of soft tissue sarcomas (STS), the choice of the proper perioperative treatment regimen is challenging. Neoadjuvant therapy has attracted increasing attention due to several advantages, particularly in patients with locally advanced disease. The number of available neoadjuvant modalities is growing continuously. We may consider radiotherapy, chemotherapy, targeted therapy, radiosensitizers, hyperthermia, and their combinations. This review discusses possible neoadjuvant treatment options in STS with an emphasis on available evidence, indications for each treatment type, and related risks. Finally, we summarize current recommendations of the STS neoadjuvant therapy response assessment.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radiation therapy
- soft tissue
- lymph node
- patients undergoing
- working memory
- stem cells
- cardiac surgery
- clinical trial
- replacement therapy
- acute kidney injury
- combination therapy
- climate change
- cell therapy
- human health
- open label
- clinical evaluation